Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.

Basit Öğe Kaydı
dc.contributor.authorIcli, F.
dc.contributor.authorAltundag, K.
dc.contributor.authorCoskun, U.
dc.contributor.authorPaydas, S.
dc.contributor.authorBasaran, G.
dc.contributor.authorSaip, P.
dc.contributor.authorDogu, G. G.
dc.date.accessioned2024-04-24T17:14:57Z
dc.date.available2024-04-24T17:14:57Z
dc.date.issued2011
dc.departmentDicle Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.doi10.1200/jco.2011.29.15_suppl.629
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15en_US
dc.identifier.urihttps://doi.org/10.1200/jco.2011.29.15_suppl.629
dc.identifier.urihttps://hdl.handle.net/11468/18272
dc.identifier.volume29en_US
dc.identifier.wosWOS:000208880300132
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleNine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu